Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Targeting LIM kinases in taxane resistant tumors.

Prunier C, Kapur R, Lafanechère L.

Oncotarget. 2016 Aug 9;7(32):50816-50817. doi: 10.18632/oncotarget.10816. No abstract available.

2.

Enhancement of paclitaxel-induced breast cancer cell death via the glycogen synthase kinase-3β-mediated B-cell lymphoma 2 regulation.

Noh KT, Cha GS, Kang TH, Cho J, Jung ID, Kim KY, Ahn SC, You JC, Park YM.

BMB Rep. 2016 Jan;49(1):51-6. doi: 10.5483/BMBRep.2016.49.1.102.

3.

Utilizing Yeast Surface Human Proteome Display Libraries to Identify Small Molecule-Protein Interactions.

Bidlingmaier S, Liu B.

Methods Mol Biol. 2015;1319:203-14. doi: 10.1007/978-1-4939-2748-7_11.

4.

Biomathematical description of synthetic peptide libraries.

Sieber T, Hare E, Hofmann H, Trepel M.

PLoS One. 2015 Jun 4;10(6):e0129200. doi: 10.1371/journal.pone.0129200. eCollection 2015.

5.

Mechanisms of distal axonal degeneration in peripheral neuropathies.

Cashman CR, Höke A.

Neurosci Lett. 2015 Jun 2;596:33-50. doi: 10.1016/j.neulet.2015.01.048. Epub 2015 Jan 21. Review.

6.

Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases.

Uversky VN, Davé V, Iakoucheva LM, Malaney P, Metallo SJ, Pathak RR, Joerger AC.

Chem Rev. 2014 Jul 9;114(13):6844-79. doi: 10.1021/cr400713r. Epub 2014 May 15. Review. No abstract available.

7.

BamHI-A rightward frame 1, an Epstein-Barr virus-encoded oncogene and immune modulator.

Hoebe EK, Le Large TY, Greijer AE, Middeldorp JM.

Rev Med Virol. 2013 Nov;23(6):367-83. doi: 10.1002/rmv.1758. Epub 2013 Aug 31. Review.

8.

Development of Next-Generation Peptide Binders Using In vitro Display Technologies and Their Potential Applications.

Wada A.

Front Immunol. 2013 Aug 1;4:224. doi: 10.3389/fimmu.2013.00224. eCollection 2013.

9.

Molecular basis for the action of a dietary flavonoid revealed by the comprehensive identification of apigenin human targets.

Arango D, Morohashi K, Yilmaz A, Kuramochi K, Parihar A, Brahimaj B, Grotewold E, Doseff AI.

Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):E2153-62. doi: 10.1073/pnas.1303726110. Epub 2013 May 22.

10.

GuiTope: an application for mapping random-sequence peptides to protein sequences.

Halperin RF, Stafford P, Emery JS, Navalkar KA, Johnston SA.

BMC Bioinformatics. 2012 Jan 3;13:1. doi: 10.1186/1471-2105-13-1.

11.

Mitochondrial abnormality in sensory, but not motor, axons in paclitaxel-evoked painful peripheral neuropathy in the rat.

Xiao WH, Zheng H, Zheng FY, Nuydens R, Meert TF, Bennett GJ.

Neuroscience. 2011 Dec 29;199:461-9. doi: 10.1016/j.neuroscience.2011.10.010. Epub 2011 Oct 19.

12.
13.

Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides.

Li J, Feng L, Fan L, Zha Y, Guo L, Zhang Q, Chen J, Pang Z, Wang Y, Jiang X, Yang VC, Wen L.

Biomaterials. 2011 Jul;32(21):4943-50. doi: 10.1016/j.biomaterials.2011.03.031. Epub 2011 Apr 5.

14.

Paclitaxel accelerates spontaneous calcium oscillations in cardiomyocytes by interacting with NCS-1 and the InsP3R.

Zhang K, Heidrich FM, DeGray B, Boehmerle W, Ehrlich BE.

J Mol Cell Cardiol. 2010 Nov;49(5):829-35. doi: 10.1016/j.yjmcc.2010.08.018. Epub 2010 Aug 27.

15.

Intrinsically disordered proteins are potential drug targets.

Metallo SJ.

Curr Opin Chem Biol. 2010 Aug;14(4):481-8. doi: 10.1016/j.cbpa.2010.06.169. Epub 2010 Jul 2. Review.

16.

A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors.

Liu G, Kolesar J, McNeel DG, Leith C, Schell K, Eickhoff J, Lee F, Traynor A, Marnocha R, Alberti D, Zwiebel J, Wilding G.

Clin Cancer Res. 2008 May 1;14(9):2732-9. doi: 10.1158/1078-0432.CCR-07-1490.

17.

Conformational analysis of the carboxy-terminal tails of human beta-tubulin isotypes.

Luchko T, Huzil JT, Stepanova M, Tuszynski J.

Biophys J. 2008 Mar 15;94(6):1971-82. Epub 2007 Nov 9.

18.

Chronic exposure to paclitaxel diminishes phosphoinositide signaling by calpain-mediated neuronal calcium sensor-1 degradation.

Boehmerle W, Zhang K, Sivula M, Heidrich FM, Lee Y, Jordt SE, Ehrlich BE.

Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11103-8. Epub 2007 Jun 20.

19.

Paclitaxel induces calcium oscillations via an inositol 1,4,5-trisphosphate receptor and neuronal calcium sensor 1-dependent mechanism.

Boehmerle W, Splittgerber U, Lazarus MB, McKenzie KM, Johnston DG, Austin DJ, Ehrlich BE.

Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18356-61. Epub 2006 Nov 17.

20.

Mitochondria: pharmacological manipulation of cell death.

Bouchier-Hayes L, Lartigue L, Newmeyer DD.

J Clin Invest. 2005 Oct;115(10):2640-7. Review.

Supplemental Content

Support Center